StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a research report sent to investors on Saturday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Pulmatrix Stock Performance
Shares of NASDAQ PULM opened at $2.06 on Friday. Pulmatrix has a 52-week low of $1.55 and a 52-week high of $2.75. The firm has a market capitalization of $7.52 million, a price-to-earnings ratio of -0.70 and a beta of 0.99. The stock has a 50 day moving average price of $2.07 and a 200 day moving average price of $2.03.
Pulmatrix (NASDAQ:PULM – Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter. The firm had revenue of $1.55 million for the quarter. Pulmatrix had a negative return on equity of 46.86% and a negative net margin of 95.18%.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Articles
- Five stocks we like better than Pulmatrix
- How to Calculate Stock Profit
- Palantir Cracks $50, Is There Still Time to Get on Board?
- What is a Dividend King?
- Insider Buying Signals Upside for These 3 Stocks
- What is MarketRank™? How to Use it
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
